荣昌生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：抗癌药物、抗癌治 癌、眼科概念、创新药、年度强势等。 截至9月30日，荣昌生物股东户数1.53万，较上期增加18.33%；人均流通股10639股，较上期减少 15.54%。2025年1月-9月，荣昌生物实现营业收入17.20亿元，同比增长42.27%；归母净利润-5.51亿元， 同比增长48.60%。 荣昌生物今年以来股价涨203.29%，近5个交易日跌1.01%，近20日跌0.74%，近60日跌1.58%。 今年以来荣昌生物已经4次登上龙虎榜，最近一次登上龙虎榜为6月26日，当日龙虎榜净买入-1.37亿 元；买入总计2.35亿元 ，占总成交额比15.86%；卖出总计3.72亿元 ，占总成交额比25.12%。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及 双抗等治疗性抗体药物领域。公司致 ...

荣昌生物今年以来股价涨209.70%，近5个交易日涨6.57%，近20日跌3.61%，近60日跌3.69%。 今年以来荣昌生物已经4次登上龙虎榜，最近一次登上龙虎榜为6月26日，当日龙虎榜净买入-1.37亿 元；买入总计2.35亿元 ，占总成交额比15.86%；卖出总计3.72亿元 ，占总成交额比25.12%。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及 双抗等治疗性抗体药物领域。公司致力于发现、开发与商业化创新、有特色的同类首创(first-in-class)与 同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重 大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。主营业务收入 构成为：销售商品99.46%，出售材料0.38%，租赁服务0.16%。 荣昌生物所属申万行业为： ...

Core Viewpoint - Midea Medical's stock has experienced fluctuations, with a year-to-date increase of 41.57% but a recent decline in the last 5, 20, and 60 trading days [1] Financial Performance - For the period from January to September 2025, Midea Medical achieved a revenue of 225 million yuan, representing a year-on-year growth of 2.31% [2] - The net profit attributable to the parent company was 8.84 million yuan, showing a year-on-year increase of 15.82% [2] Stock Market Activity - As of December 2, Midea Medical's stock price was 15.29 yuan per share, with a market capitalization of 2.54 billion yuan [1] - The stock has seen a net inflow of 353,400 yuan from main funds, with a significant portion of buying activity [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the last occurrence on August 26, where it recorded a net buy of -57.70 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 4,528, while the average circulating shares per person decreased by 15.97% to 36,709 shares [2] - The top ten circulating shareholders include notable funds, with some new entrants and exits among them [3] Dividend Distribution - Midea Medical has distributed a total of 202 million yuan in dividends since its A-share listing, with 99.30 million yuan distributed over the past three years [3] Business Overview - Midea Medical, established in March 2003 and listed in December 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main revenue sources are safety infusion products (48.75%), blood purification products (26.27%), and other products (24.98%) [1]

Core Viewpoint - The stock of Taiankang has shown significant volatility, with a year-to-date increase of 100.53%, but recent trends indicate a decline over the past 20 and 60 days, raising concerns about its future performance [1][2]. Financial Performance - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, representing a year-on-year decrease of 8.13% [2]. - The net profit attributable to the parent company for the same period was 31.41 million yuan, reflecting a substantial year-on-year decline of 73% [2]. Stock Market Activity - As of November 26, Taiankang's stock price was 29.66 yuan per share, with a market capitalization of 12.62 billion yuan [1]. - The trading volume on that day was 66.90 million yuan, with a turnover rate of 0.75% [1]. - The stock has experienced a net outflow of 4.76 million yuan in principal funds, indicating a lack of strong buying interest [1]. Shareholder Information - As of September 30, the number of shareholders for Taiankang increased to 12,000, a rise of 9.32% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.53% to 25,381 shares [2]. Dividend Distribution - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

11月26日，贝达药业盘中上涨2.14%，截至10:02，报50.52元/股，成交6811.19万元，换手率0.32%，总 市值212.55亿元。 资金流向方面，主力资金净流入438.16万元，大单买入1300.33万元，占比19.09%，卖出862.17万元，占 比12.66%。 分红方面，贝达药业A股上市后累计派现6.69亿元。近三年，累计派现1.84亿元。 机构持仓方面，截止2025年9月30日，贝达药业十大流通股东中，兴全商业模式混合(LOF)A（163415） 位居第五大流通股东，持股582.70万股，为新进股东。易方达创业板ETF（159915）位居第六大流通股 东，持股545.55万股，相比上期减少91.23万股。兴全合润混合A（163406）位居第七大流通股东，持股 540.17万股，为新进股东。中欧医疗健康混合A（003095）、南方中证500ETF（510500）退出十大流通 股东之列。 责任编辑：小浪快报 资料显示，贝达药业股份有限公司位于浙江省杭州市临平区经济技术开发区兴中路355号,香港铜锣湾希 慎道33号利园1期19楼1919室，成立日期2003年1月7日，上市日期2016年11月 ...

Core Points - Boda Pharmaceutical's stock price decreased by 2.08% on November 21, reaching 49.06 CNY per share, with a market capitalization of 20.641 billion CNY [1] - The company has experienced a year-to-date stock price decline of 8.69%, with a 9.68% drop over the last five trading days and a 23.44% decline over the past 60 days [1] - As of September 30, 2025, Boda Pharmaceutical reported a revenue of 2.717 billion CNY, a year-on-year increase of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2] Financial Performance - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2] Shareholder Structure - Among the top ten circulating shareholders, Xingshan Commercial Model Mixed Fund A is the fifth largest with 5.827 million shares, marking a new entry [3] - E Fund's Growth Enterprise Board ETF, ranked sixth, reduced its holdings by 912,300 shares to 5.456 million shares [3] - Xingshan Helun Mixed Fund A is the seventh largest shareholder with 5.402 million shares, also a new entry [3]

Core Viewpoint - Benda Pharmaceutical's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and market capitalization, indicating potential challenges in the company's performance and investor sentiment [1][2]. Company Performance - As of September 30, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - The company's stock price has fallen by 5.40% year-to-date, with a 5.71% decline over the past five trading days, a 12.75% drop over the last 20 days, and a significant 27.60% decrease over the past 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - Benda Pharmaceutical has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include Xingquan Commercial Model Mixed Fund (LOF) A, which is the fifth-largest shareholder with 5.827 million shares, and E-Fund's Growth Enterprise Board ETF, which has reduced its holdings by 912,300 shares [3].

Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

11月19日，京新药业盘中下跌2.01%，截至09:38，报20.48元/股，成交1.27亿元，换手率0.85%，总市值 176.34亿元。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：阿尔茨海默、抗癌治 癌、眼科概念、生物医药、创新药等。 截至9月30日，京新药业股东户数2.23万，较上期减少13.08%；人均流通股32438股，较上期增加 15.05%。2025年1月-9月，京新药业实现营业收入30.48亿元，同比减少5.00%；归母净利润5.76亿元，同 比增长0.10%。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年9月30日，京新药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股745.88万股，相比上期减少219.04万股。 责任编辑：小浪快报 资金流向方面，主力资金净流出165.99万元，特大单买入628.85万元，占比4.95%，卖出725.96万元，占 比5.71%；大单买入2673.29万元，占比21.04%，卖出2742.17万元，占比21.58%。 京新药业今年以来股价涨64 ...

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 34.88% [1] - As of November 17, the stock price is reported at 61.64 CNY per share, with a total market capitalization of 409.12 billion CNY [1] - The company has seen a net outflow of 1.92 million CNY in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, focuses on the research, production, and sales of pharmaceuticals, particularly in the oncology field [2] - The company's main revenue sources are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2] - The company operates in various therapeutic areas, including oncology, pain management, and cardiovascular diseases [2] Group 3 - As of September 30, the number of shareholders has increased to 397,300, while the average circulating shares per person have decreased by 8.21% [3] - For the period from January to September 2025, 恒瑞医药 reported a revenue of 23.188 billion CNY, reflecting a year-on-year growth of 14.85%, and a net profit of 5.751 billion CNY, up 24.50% year-on-year [3] Group 4 - Since its A-share listing, 恒瑞医药 has distributed a total of 9.303 billion CNY in dividends, with 3.568 billion CNY distributed in the last three years [4] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 487 million shares, a decrease of 48.179 million shares from the previous period [4] - Other notable shareholders include China Securities Finance Corporation and various ETFs, with some experiencing a reduction in shareholding [4]